A5069547779- PARP inhibition in cancer therapy
- Ovarian cancer diagnosis and treatment
- Cancer Genomics and Diagnostics
- Cardiac electrophysiology and arrhythmias
- Poisoning and overdose treatments
- Urologic and reproductive health conditions
- Prostate Cancer Diagnosis and Treatment
- Ion channel regulation and function
- Analytical Methods in Pharmaceuticals
- Genital Health and Disease
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Urological Disorders and Treatments
Ontario Institute for Cancer Research
2023-2025
Jamaica Hospital
2016
To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms resistance PARP inhibitors (PARPi) in high-grade serous ovarian cancer (HGSOC).
Loperamide is over-the-counter antidiarrheal agent acting on peripherally located μ opioid receptors. It gaining popularity among drug abusers as substitute. We report a case of 46-year-old male that was presented after cardiac arrest. After ruling out ischemia, cardiomyopathy, pulmonary embolism, central nervous system pathology, sepsis, and other toxicity, we found patient using around 100 mg to control his chronic diarrhea presumably because irritable bowel syndrome for last five years...
Purpose: Optimal maintenance strategy following re-challenge with platinum-based chemotherapy in patients relapsed high grade serous ovarian cancer (HGSOC) after PARP inhibitor (PARPi) therapy remains to be established. Use of cell-free DNA (cfDNA) sequencing detect minimal residual disease (MRD) has emerged as a promising identify at higher risk relapse who might benefit from more timely, additional treatment. Methods: Nineteen histologically confirmed TP53 mutant HGSOC platinum sensitive...
Primary transitional cell carcinoma of the prostate is a rare clinicopathological entity. It an aggressive tumor with poor prognosis. Presentation usually late, obstructive voiding complaints. Radical surgery offers locoregional control disease. We report case atypical presentation bleeding per rectum and associated symptoms. Examination revealed rectal ulcer overlying enlarged fixed to it. Histopathology showed picture infiltrating rectum. Imaging studies altered echo pattern spread,...
<p>Supplementary Figure 5: Sensitivity of variant calling methods on cfDNA</p>
<p>Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features</p>
<p>Supplementary Figure 3: Distribution of ctDNA levels and statistical association with clinical features</p>
<p>Supplementary Figure 7: Copy-number profile of CCNE1 in cfDNA</p>
<div>Abstract<p>Purpose To evaluate the use of blood cell-free DNA (cfDNA) to identify emerging mechanisms resistance PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Patients and Methods We used targeted sequencing (TS) analyse 78 longitudinal cfDNA samples collected from 30 patients with HGSOC enrolled a phase II clinical trial evaluating cediranib (VEGF inhibitor) plus olaparib after progression on PARPi alone. was at baseline, before treatment cycle 2, end...
<p>Supplementary Figure 4: Distribution of cfDNA fragment length</p>
<p>Supplementary Figure 1: Establishment of limit detection (LOD) for targeted sequencing panel on ctDNA</p>
<p>Supplementary Figure 5: Sensitivity of variant calling methods on cfDNA</p>
<p>Supplementary Figure 6: Visualization of structural variants in cfDNA</p>
<p>Supplementary Figure 1: Establishment of limit detection (LOD) for targeted sequencing panel on ctDNA</p>